Jkj, excellent post and I can't wait to hear the science posters weigh in on thus.

What this brings to mind for me is that in the combined ASSURE/SUSTAIN trial post hoc analysis within the diabetes mellitus patients with CVD and low HDL the results after 210 days were as follows:

Control group - standard of care on Crestor only - MACE events at 210 days were 21%.

Test group - standard of care on Crestor plus rvx-208 - MACE events 5.1%.

Relative risk reduction = 77%.

Absolute risk reduction = 15.9% points. Many lives saved.

If rvx-208 can't get BETonMACE FDA approval with high priority it is a sad state of affairs and I almost wonder if it's because RVX is Canadian based?

Thank again.

Toinv